CLL: chronic lymphocytic leukemia; SLL: small lymphocytic lymphoma; IGHV: immunoglobulin heavy-chain variable region; TP53: tumor protein p53; ORR: overall response rate; TLS: tumor lysis syndrome; VEN: venetoclax; B: bendamustine; R: rituximab; G: obinutuzumab; PFS: progression-free survival; R-ref: rituximab-refractory; F-ref: fludarabine-refractory; MRD: minimal residual disease. Here, TP53 is linked to Tumor Lysis Syndrome.